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Abstract
Fatty acid synthase (FASN) is the only human lipogenic enzyme available for de novo fatty acid synthesis and is often
highly expressed in cancer cells. We found that FASN mRNA levels were significantly higher in acute myeloid leukemia
(AML) patients than in healthy granulocytes or CD34+ hematopoietic progenitors. Accordingly, FASN levels decreased
during all-trans retinoic acid (ATRA)-mediated granulocytic differentiation of acute promyelocytic leukemia (APL) cells,
partially via autophagic degradation. Furthermore, our data suggest that inhibition of FASN expression levels using RNAi or
(-)-epigallocatechin-3-gallate (EGCG) accelerated the differentiation of APL cell lines and significantly re-sensitized ATRA
refractory non-APL AML cells. FASN reduction promoted translocation of transcription factor EB (TFEB) to the nucleus,
paralleled by activation of CLEAR network genes and lysosomal biogenesis. Together, our data demonstrate that inhibition
of FASN expression in combination with ATRA treatment facilitates granulocytic differentiation of APL cells and may
extend differentiation therapy to non-APL AML cells.
Introduction
While traditional chemotherapy and radiotherapy target
highly proliferative cancer cells, differentiation-inducing
therapy aims to restore differentiation programs to drive
cancer cells into maturation and ultimately into cell death.
Differentiation therapies are associated with lower toxicity
compared to classical cytotoxic therapies. The success of
this therapeutic approach is exemplified by the introduction
of all-trans retinoic acid (ATRA) in 1985 to treat acute
promyelocytic leukemia (APL) [1]. The introduction of
ATRA into the treatment regimen changed APL from being
one of the most aggressive acute myeloid leukemia (AML)
subtypes with a fatal course often within weeks only, to a
curable disease with a complete remission rate of up to 95%
when combined with anthracycline-based chemotherapy or
arsenic trioxide [1]. APL is characterized by translocations
involving the C-terminus of the retinoic acid receptor alpha
(RARA) on chromosome 17 and genes encoding for
aggregate prone proteins. Promyelocytic leukemia (PML)-
RARA is the most frequently expressed fusion protein. It is
encoded by the translocation t(15;17) and has a dominant-
negative effect on RARA. RARA transcriptionally regulates
multiple biological processes with a key role in differ-
entiation [2]. Several reports suggest a beneficial effect of
ATRA in combination therapies in non-APL AML cells
[3–5]. Unfortunately, a variety of intrinsic resistance
mechanisms in non-APL AML have been identified such as
SCL overexpression, expression of PRAME and epigenetic
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silencing or mutation of RARA [6–9]. Deciphering the
mechanisms active during ATRA-mediated differentiation
at the molecular level will support the translation of dif-
ferentiation therapy to non-APL AML patients. We and
others have demonstrated the importance of autophagy in
ATRA induced granulocytic differentiation of APL cells
[10–15]. Autophagy is an intracellular degradation
mechanism that ensures dynamic recycling of various
cytoplasmic contents [16]. We thus aim to understand the
role of autophagy in granulocytic differentiation and to
define key druggable autophagy targets in this process.
Endogenous synthesis of fatty acids is catalyzed by fatty
acid synthase (FASN), the only human lipogenic enzyme able
to perform de novo synthesis of fatty acids [17, 18]. FASN is
frequently overexpressed in a variety of tumor types including
leukemias [19–25] while its expression in healthy adult tissues
is low [26], with the exception of the cycling endometrium
[27] and lactating breast [28]. Interestingly, FASN is upre-
gulated in tumor-associated myeloid cells where it activates
nuclear receptor peroxisome-proliferator-activated receptor
beta/delta (PPARβ/δ) [29], a key metabolic transcription factor
in tumorigenesis [30, 31]. Of note, activation of PPARβ/δ
regulates anti-inflammatory phenotypes of myeloid cells in
other biological contexts such as atherosclerosis and obesity
[32–35]. We previously reported that (-)-epigallocatechin-3-
gallate (EGCG) improved ATRA-induced differentiation of
APL cells by increasing the expression of death-associated
protein kinase 2 (DAPK2). Furthermore, EGCG treatment
reduces FASN expression levels in selected breast cancer cell
lines [36]. The increased FASN expression in cancers
including leukemias, its function in tumor-associated myeloid
cells and its link to the differentiation enhancer DAPK2
prompted us to analyze the regulation and function of FASN
during myeloid leukemic differentiation.
In the present study, we demonstrate that FASN expression
is significantly higher in AML blasts partially due to low
autophagic activity in those cells. We show that inhibiting
FASN protein expression, but not its enzymatic activity,
promotes differentiation of non-APL AML cells. Lastly, we
link FASN expression to mTOR activation and inhibition of
the key lysosomal biogenesis transcription factor TFEB.
Material and methods
Primary cells, cell lines and culture conditions
Fresh leukemic blast cells from untreated AML patients at
diagnosis were obtained from the Inselspital Bern (Swit-
zerland) were classified according to the French-
American-British classification and cytogenetic analysis.
All leukemia samples had blast counts of ~90% after
separation of mononuclear cells using a Ficoll gradient
(Lymphoprep; Axon Lab AG, Switzerland), as described
previously [37]. Protocols and use of 67 human samples
acquired in Bern were approved by the Cantonal Ethical
Committee at the Inselspital. The isolation of primary
neutrophils (purity 95%) was performed by separating
blood cells from healthy donors using polymorphprep
(Axon Lab AG, Switzerland). CD34+ cells from cord
blood or bone marrow were isolated as previously
described [37].
The human AML cell lines HT93, OCI/AML2, MOLM-
13 and NB4 were obtained from the Deutsche Sammlung
von Mikroorganismen und Zellkulturen GmbH (DSMZ,
Braunschweig, Germany). All cell lines were maintained in
RPMI-1640 with 10% fetal calf serum, 50 U/mL penicillin
and 50 µg/mL streptomycin in a 5% CO2-95% air humidi-
fied atmosphere at 37 °C. For differentiation experiments,
AML cells were treated with 1 μM ATRA (ATRA; Sigma-
Aldrich, Switzerland). Successful granulocyte differentia-
tion was evidenced by CD11b surface expression measured
by FACS.
293 T cells were maintained in DMEM (Sigma-Aldrich,
St. Louis, MO, USA), supplemented with 5% FBS, 1%
penicillin/streptomycin, and 1% Hepes (Sigma-Aldrich,
Switzerland), and kept in a 7.5%CO2-95% air humidified
atmosphere at 37 °C.
Antibodies
Antibodies used were anti-FASN (3180; Cell Signaling,
Switzerland), anti-LC3B (WB: NB600-1384, Novus bio-
logical, Switzerland; IF: 3868; Cell Signaling, Switzerland)
anti-LAMP1 (14-1079-80; Thermofisher, Switzerland),
anti-p62 (HPA003196; Sigma-Aldrich, Switzerland), anti-
TFEB (4240; Cell Signaling, Switzerland), anti-p-TFEB
(Ser 211) (37681S, Cell Signaling, Switzerland), anti-p-
AKT (Ser473) (4060S, Cell Signaling, Switzerland) anti-
PTEN (9552, Cell Signaling, Switzerland), anti-ULK1
(4776; Cell Signaling, Switzerland), anti-p-ULK1 (Ser757,
equivalent to Ser758 of human ULK1) (6888; Cell Sig-
naling, Switzerland), anti-ATG13 (6940; Cell Signaling,
Switzerland), anti-pATG13 (Ser318) (600-401-C49;
Rockland, Switzerland), anti p-mTOR (Ser2448) (5536;
Cell Signaling, Switzerland), p4E-BP1 (Thr37/46) (2855;
Cell Signaling, Switzerland), anti-α-tubulin (3873; Cell
Signaling, Switzerland), anti-cleaved PARP (9541; Cell
Signaling, Switzerland), anti yH2AX (2577; Cell Signal-
ing, Switzerland) and anti-CD11b-PE (R0841; Dako,
Switzerland).
Cell lysate preparation and western blotting
Whole-cell extracts were prepared using UREA lysis buffer
and 30–60 μg of total protein was loaded on a 7.5% or 12%
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denaturing polyacrylamide self-cast gels (Bio-Rad, Swit-
zerland). Blots were incubated with the primary antibodies
in TBS 0.05% Tween-20/5% milk overnight at 4 °C and
subsequently incubated with HRP coupled secondary goat
anti-rabbit (7074; Cell Signaling, Switzerland) and goat
anti-mouse antibody (7076; Cell Signaling, Switzerland) at
1:5–10,000 for 1 h at room temperature. Blots were imaged
using Chemidoc (Bio-Rad, Switzerland) and ImageLab
software.
Lentiviral vectors
pLKO.1-puro lentiviral vectors expressing shRNAs targeting
FASN (shFASN_1: NM_004104.x-1753s1c1 and shFASN_2:
NM_004104.x-3120s1c1) were purchased from Sigma-
Aldrich. A mCherry-LC3B lentiviral vector was kindly pro-
vided by Dr. Maria S. Soengas (CNIO, Molecular Pathology
Program, Madrid, Spain). All vectors contain a puromycin
antibiotic resistance gene for the selection of transduced
mammalian cells. Lentivirus production and transduction
were performed as previously described [37, 38]. Transduced
NB4, MOLM-13 and OCI/AML2 cell populations were
selected with 1.5 µg/ml puromycin for 4 days and knockdown
efficiency was assessed by western blot analysis.
Immunofluorescence microscopy
Cells were prepared as previously described [14]. Briefly,
cells were fixed and permeabilized with ice-cold 100%
methanol for 4 min (FASN, mTOR, LC3B and
LAMP1 staining) or 2% paraformaldehyde for 7 min fol-
lowed by 5min in PBS 0.1% TRITON X-100 (TFEB and
tubulin staining) and then washed with PBS. Cells were
incubated with primary antibody for 1 h at room temperature
followed by washing steps with PBS containing 0.1% Tween
(PBS-T). Cells were incubated with the secondary antibody
(anti-rabbit, 111-605-003 (Alexa Fluor® 647) 111-096-045
(FITC); anti-mouse, (Cy3) 115-605-003 (Alexa Fluor® 647);
Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at
room temperature. Prior to mounting in fluorescence mount-
ing medium (S3032; Dako, Switzerland) cells were washed
three times with PBS-Tween. Images were acquired on an
Olympus FluoView-1000 confocal microscope (Olympus,
Volketswil, Switzerland) at ×63 magnification.
Acridine Orange staining
Cells were washed three times with PBS and resuspended
in RPMI 10% FBS containing 5ug/mL Acridine Orange
(A3568, Invitrogen, Switzerland) to a concentration of
0.2 × 106 cells per ml. Cells were then incubated at 37 °C
for 20 min and washed three times with PBS. Acridine
Orange staining was measured by FACS analysis using a
488 nm laser with 530/30 (GREEN) and 695/40 (RED)
filters on a FACS LSR-II (BD Biosciences, Switzerland).
Data were analyzed with FlowJo software (Ashland, OR,
USA). The software derived the RED/GREEN ratio and
we compared the distribution of populations using the
Overton cumulative histogram subtraction algorithm to
provide the percentage of cells more positive than the
control.
Nitroblue tetrazolium reduction test
Suspension cells (5 × 105) were resuspended in a 0.2% nitro
blue tetrazolium (NBT) solution containing 40 ng/ml PMA
and incubated 15 min at 37 °C. Cells were then washed with
PBS and subjected to cytospin. Counterstaining was done
with 0.5% Safranin O for 5 min (HT90432; Sigma-Aldrich,
Switzerland). The NBT-positive and negative cells were
scored under a light microscope (EVOS XL Core, Ther-
mofisher, Switzerland).
Trypan blue exclusion counting
Trypan blue exclusion cell counting was performed to
assess cellular growth. 20 µL of cell suspension was incu-
bated with an equal volume of 0.4% (w/v) trypan blue
solution (Sigma-Aldrich, Switzerland). Cells were counted
using a dual-chamber hemocytometer and a light micro-
scope (EVOS XL Core, Thermofisher, Switzerland).
Real-time quantitative RT-PCR (qPCR)
Total RNA was extracted using the RNeasy Mini Kit and
the RNase-Free DNase Set according to the manufacturer’s
protocol (Sigma-Aldrich, Switzerland). Total RNA was
reverse transcribed using all-in-one RT-PCR (BioTool,
Switzerland). Taqman® Gene Expression Assays for FASN,
ELOVL6, SCD1, ACACA, BECN1, GABARAP, STK4, and
WDR45 were Hs01005632_g1, Hs00907564_m1,
Hs01682761_m1, Hs01046047_m1, Hs00186838_m1,
Hs00925899_g1, Hs00178979_m1 and Hs01079049_g1,
respectively. Specific primers and probes for HMBS have
been already described [37]. Data represent the mean ± s.d.
of at least two independent experiments.
TaqMan low-density array (LDA)
Total RNA was extracted using the Qiagen RNeasy kit and the
RNase-Free DNase Set to minimize the risk of contamination
with genomic DNA, according to the manufacturer’s protocol
(Qiagen AG). 1–2 μg of total RNA was reverse transcribed
using pd(N)6 random primers (Roche Diagnostics AG,
Rotkreuz, Switzerland). Real-time RT-PCR for LDAs was
performed using the ABI 7900HT Fast Real-Time PCR
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System (Applied Biosystems, Rotkreuz, Switzerland) and 400
ng of cDNA. Taqman® Gene Expression Assays for HMBS,
ABL1, and FASN preloaded on LDAs or used in a 96-well
format using the ABI PRISM 7700 Sequence Detection
System were Hs00609297_m1, Hs00245445_m1, and
Hs01005632_g1 respectively (Applied Biosystems).
Measured cycle threshold (Ct) values represent log 2
expression levels. Values were normalized to the expression
levels of two housekeeping genes HMBS and ABL1 as
described in [39].
Lipid extraction
The protocol was performed as previously described [40].
Briefly, NB4 cells (0.5 × 105 cells/ml) were labelled with
0.5 µCi/ml [14C]-Acetic Acid [American Radiolabeled
Chemical Inc., St. Louis, MO, USA] for 6 h in the presence
or absence of different concentrations of C75 and Orlistat.
Cells were harvested using 0.5 ml PBS and lipids were
extracted using chloroform/methanol (3:1, v/v). The
chloroform phase was evaporated under nitrogen and con-
centrated lipids were dissolved in 30 µl dichloromethane.
Lipids were separated by thin layer chromatography over
silicagel (SIL G/UV254) TLC plates (Macherey-Nagel,
Oensingen, Switzerland) using hexane/diethyl ether/acetic
acid (70:30:1, v/v) as mobile phase. Palmitic acid (PA)
spots were identified using a standard [Sigma-Aldrich,
Basel, Switzerland] solution by exposing the TLC to Iodine
vapor. The corresponding radiolabeled spots were visua-
lized by autoradiography using a Fuji FLA-7000 Phos-
phoImager (Fujifilm, Dielsdorf, Switzerland) and quantified
using ImageQuant software. The amount of PA formed in
the presence of drugs was calculated as a percent of
radioactivity incorporated into the control samples.
Statistical analysis
Nonparametric Mann–Whitney-U tests were applied to
compare the difference between two groups and Spearman
Coefficient Correlation using Prism software (GraphPad
Software, Inc., Jolla, CA, USA). P values < 0.05 were
considered statistically significant. The error bar on graphs
represents the SD of at least two biological replicates per-
formed in two technical replicates.
Results
Primary AML blast cells express significantly higher
FASN levels compared to mature granulocytes
Cancer cells frequently express high levels of FASN com-
pared to their healthy counterparts [19–25]. We examined
FASN mRNA expression in an AML patient cohort. FASN
mRNA levels in AML samples (n= 68) were compared to
the levels in granulocytes (n= 5) and CD34+ human
hematopoietic progenitor cells (n= 3) from healthy donors.
We found that FASN expression was significantly higher in
AML patients compared to healthy granulocytes (p < 0.05)
(Fig. 1A). We obtained similar findings by analyzing FASN
expression in AML patient data available from the Blood
spot gene expression profile data base [41] (Fig. 1B). In
addition, hematopoietic stem cells from healthy donors
express significantly lower FASN mRNA transcript levels
than AML blasts (Fig. 1B). Next, we asked if FASN
expression was altered during granulocytic differentiation
of APL cells. We analyzed FASN protein expression fol-
lowing ATRA-induced differentiation of two APL cell
lines, NB4 and HT93. Successful differentiation was con-
firmed by flow cytometry, using CD11b surface marker
expression (Supplementary Fig. 1A-C). ATRA treatment
resulted in markedly reduced FASN protein levels from day
two onwards (Fig. 1C) whereas FASN mRNA levels did not
decrease (Fig. 1D). Interestingly, other transcriptional tar-
gets of the sterol regulatory element binding protein 1
(SREBP1), such as ELOVL6, SCD1 and ACACA, were
upregulated, yet FASN (also a transcriptional target), was
not (Supplementary Fig. 1C). Collectively this data suggests
that high FASN expression is linked to an immature blast-
like phenotype and that the decrease in FASN protein levels
during ATRA-induced differentiation is mediated at the
protein level, rather than by transcriptional mechanisms.
FASN protein is degraded via macroautophagy
during ATRA-induced granulocytic differentiation
We and others have demonstrated that autophagy gene
expression is repressed in AML samples compared to
granulocytes from healthy donors and that autophagy
activity is essential for successful ATRA-induced APL
differentiation [10–15, 42]. The marked decrease in FASN
protein upon ATRA-induced differentiation is likely to be
due to post-transcriptional regulation as transcript levels are
unchanged and the protein has a long half-life (1–3 days)
[26, 43]. Moreover, FASN has been detected inside
autophagosomes, for instance in yeast and in the breast
cancer cell line MCF7 [44, 45]. Therefore, we hypothesized
that ATRA-induced autophagy participates in the degrada-
tion of FASN during differentiation of APL cells. To
examine whether autophagy is involved in FASN degra-
dation, we treated NB4 cells for 24 h with different con-
centrations of Bafilomycin A1 (BafA1), a specific inhibitor
of vacuolar-type H+-ATPase [46, 47], alone or in combi-
nation with ATRA. FASN protein was found to accumulate
in the presence of BafA1 at day 1 and 2 of ATRA treatment
in NB4 cells, together with autophagy markers p62 and
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LC3B-II (Fig. 2A-B). To validate these findings, we utilized
NB4 cells stably expressing mCherry-LC3B. Cells were
treated with different concentrations of BafA1 with or
without ATRA for 24 h and FASN, as well as LC3B
localization, was assessed. Endogenous FASN (cyan)
showed colocalization with mCherry-LC3B (red) in BafA1
and ATRA treated cells (Fig. 2C). In addition, we found
colocalization with endogenous FASN (red) and p62
(green) in NB4 parental cells treated with both ATRA and
BafA1 for 24 h (Fig. 2D). It is possible that p62 may help to
sequester FASN to the autophagosome. These data suggest
that FASN is a target for autophagic degradation during
granulocytic differentiation of APL cells.
We have previously shown that EGCG improves the
response to ATRA in AML cells by inducing DAPK2
expression, a key kinase in granulocytic differentiation [48].
Furthermore, EGCG was reported to decrease FASN
expression [36] and this was reproducible in our APL cell
line model (Supplementary Fig. 2A-B). Using different
EGCG doses and treatment time points, we confirmed that
EGCG improves ATRA-induced differentiation in NB4
cells, as evidenced by increased NBT positive cells and
CD11b surface expression (Supplementary Fig. 2C-E).
Importantly, increased differentiation when combining
ATRA with EGCG was paralleled by enhanced autophagic
activity (Supplementary Fig. 2F-G). Autophagy induction
Fig. 1 Increased FASN expression is associated with an immature
AML blast phenotype. A FASN mRNA levels in AML blasts, CD34+
progenitor cells and granulocytes from healthy donors were quantified
by qPCR. All the samples were obtained from the Inselspital, Bern,
Switzerland. AML patient cells and granulocytes were isolated using
Ficoll gradient density centrifugation. Values are the differences in Ct-
values between FASN and the housekeeping genes HMBS and ABL1.
MNW *p < 0.05, **p < 0.0. B Blood spot data bank analysis of FASN
expression in AML blasts compared to granulocytes from healthy
donors. MNW *p < 0.05, **p < 0.01. C Western blot analysis of FASN
regulation in NB4 and HT93 APL cells upon ATRA treatment at dif-
ferent time points (1, 2 and 3 days). Total protein was extracted and
submitted to immunoblotting using anti-FASN antibody. Total protein
is shown as loading control. The relative protein expressions were
normalized to total protein and quantified using ImageJ software (NIH,
Bethesda, MD, USA). Data are represented as a mean (n= 3), Error
bars: SD. D Evaluation of FASN transcript levels upon ATRA treat-
ment was done by qPCR. Values were normalized to the HMBS
housekeeping gene. Results of at least three independent experiments
are shown as n-fold regulation compared with non-treated cells.
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was determined by quantifying endogenous, lipidated
LC3B-II by western blotting and a dual-tagged mCherry-
GFP-LC3B expression construct as described previously
[13, 49, 50]. Autophagic flux quantification upon EGCG
treatment was performed in the presence or absence of
BafA1 [50]. We found no significant changes in cell death
or proliferation measured by DAPI staining and trypan
blue exclusion, respectively (Supplementary Fig. 2H-I).
Fig. 2 FASN is degraded via autophagy. A–B NB4 cells were
treated with ATRA and three concentrations of Bafilomycin A1
(BafA1) for 24 h (A) and 48 h (B). NB4 cells were lysed and subjected
to western blot analysis as described in 1C. Quantification of the bands
was done using ImageJ software and normalized to control-treated
cells. Data are represented as a mean of at least three biological
replicates, Error bars: SD. C NB4 cells stably expressing mCherry-
LC3B were treated with ATRA and different concentrations of Bafi-
lomycin A1 (BafA1) for 24 h. NB4 mCherry-LC3B cells were fixed
and stained for endogenous FASN. The colocalization analysis was
performed using ImageJ software. Scale: 10 µm D NB4 cells were
treated as in 2 C and fixed and stained for endogenous FASN and p62.
The colocalization analysis was performed using ImageJ software.
Scale: 10 µm. Results shown are from at least two biological dupli-
cates. E–G EGCG potentiate ATRA-induced FASN degradation by
autophagy. E–F FASN and p62 western blot analysis of NB4 cells
treated with DMSO (right panel) or ATRA (left panel), in combination
with different EGCG (5–15 µM) and BafA1 (100 nm) concentrations
for 24 h (E) or 48 h (F). Total cell lysates were subjected to western
blotting. G Quantification of the western blot was done as in Fig. 1C.
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Co-treating NB4 parental cells with EGCG and ATRA as
well as blocking autophagy using BafA1, resulted in a
higher accumulation of FASN protein at 24 h or 48 h
(Fig. 2E-G). Together, our data demonstrate that FASN can
be degraded via autophagy during APL cell differentiation
and that co-treatment with EGCG further promotes FASN
protein degradation.
Inhibiting FASN protein expression but not its
catalytic function accelerates ATRA-induced
granulocytic differentiation in APL cell lines
Next, we evaluated the impact of modulating FASN
expression and activity on myeloid differentiation. There-
fore, we genetically inhibited FASN expression using len-
tiviral vectors expressing two independent shRNAs
targeting FASN in the NB4 APL cell line model. Knock-
down efficiency was validated by western blotting
(Fig. 3A). We found that ATRA treatment significantly
reduced the doubling time (Supplementary Fig. 3A-B) and
lowered the accumulation of DNA damage as indicated by
yH2AX immunofluorescence staining in NB4 FASN
depleted cells (Supplementary Fig. 3C-D). Of note, at
steady-state conditions, knocking down FASN did not affect
proliferation compared to control cells. Knocking down
FASN in NB4 cells resulted in accelerated differentiation
into functional granulocytes compared to the control cells as
shown by NBT assays (Fig. 3B-C) and by CD11b surface
expression analysis (Fig. 3D). We then assessed the effects
of two pharmacological FASN inhibitors, C75 and Orlistat.
We used C75 and Orlistat concentrations that do not induce
significant cell death (Supplementary Fig. 4A-B) or
decrease proliferation (Supplementary Fig. 4C-D) to avoid
non-specific effects. Of note, FASN protein levels in APL
cells were not reduced by C75 or Orlistat treatment (Sup-
plementary Fig. 4E-F) while inhibiting its activity (Sup-
plementary Fig. 4G-H). Unexpectedly, co-treatment of NB4
cells with ATRA and C75 (Fig. 3E-G) or Orlistat (Fig. 3H-
J) did not reproduce the phenotype of the FASN knockdown
cells. Indeed, cells were differentiating similarly or less
compared to control-treated cells as demonstrated by NBT
assays (Fig. 3E-F and Fig. 3H-I) and CD11b surface
expression (Fig. 3G and Fig. 3J). Therefore, we conclude
that the catalytic activity of FASN is not involved in
impeding ATRA-mediated differentiation in NB4 cells.
FASN attenuates autophagy by increasing mTOR
activity
FASN has been previously reported to promote carcino-
genesis by activating mTOR, a master negative regulator of
autophagy, via AKT signaling in hepatocellular carcinoma
[51, 52]. ATRA treatment in APL reduces mTOR activity
leading to autophagy activation [10]. We, therefore, hypo-
thesized that FASN may negatively regulate autophagy via
mTOR in APL cells, thereby impeding ATRA-induced
differentiation. Therefore, we initially confirmed that FASN
expression impacts autophagic activity in our system.
Autophagy induction was established by quantifying
endogenous LC3B dots formation by immunofluorescence
microscopy (IF) after ATRA treatment [50]. In order to
measure autophagic flux, ATRA treatment was performed
in the presence or absence of BafA1 (Fig. 4A-B) [50]. In
addition, we looked at the direct consequences of mTOR
activity on ULK1 and ATG13 phosphorylation. ULK1
(ATG1), a key autophagy gene of the initiation complex, is
inhibited by mTOR-mediated phosphorylation at Ser757,
leading to reduced autophagic activity (Fig. 4C) [53]. In line
with FASN activating mTOR, lowering FASN expression
by shRNA (Fig. 4D) resulted in decreased mTOR phos-
phorylation at Ser2448 (Fig. 4E) and mTOR-mediated
downstream phosphorylation of ULK1 at Ser758 (Fig. 4F).
Elevated ULK1 activity was confirmed by an increase of
ATG13 activating phosphorylation at Ser318 (Fig. 4G)
[54, 55].
We then asked how FASN regulates mTOR activity.
First, we tested whether FASN is localized to the lysosome
by immunofluorescence microscopy upon ATRA treatment
in NB4 cells. Interestingly, FASN localized to LAMP1+
vesicles during steady-state conditions. Furthermore, ATRA
treatment reduced both protein and FASN localization to
LAMP1+ vesicles (Fig. 5A). In addition, lowering FASN
expression led to a reduced lysosomal localization of
mTOR (Fig. 5B). Next, we asked whether the mTOR
upstream regulators AKT and PTEN were influenced by
FASN expression. We treated FASN depleted NB4 cells for
3 days with ATRA and quantified AKT protein phosphor-
ylation and PTEN protein levels. Furthermore, we analyzed
two additional mTOR downstream targets namely p-4EBP1
(Thr37/46) and p-TFEB (Ser211). Interestingly, we found a
compensatory activation of AKT in NB4 FASN
knockdown cells while no marked differences in PTEN and
p-4EBP1 levels were seen. Of note, TFEB was less phos-
phorylated in FASN depleted than in SHC002 control NB4
cells (Fig. 5C-D).
These results suggest that FASN expression promotes
mTOR activity at the lysosomes, which in turn enhances
autophagy inhibition in AML cells.
FASN expression negatively affects transcription
factor EB (TFEB) activation
mTOR phosphorylates the transcription factor EB (TFEB),
a master regulator of lysosome biogenesis, leading to the
sequestration of TFEB within the cytoplasm and inhibition
of its transcriptional activity [56–59]. TFEB is a key
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transcriptional regulator of more than 500 genes that com-
prise the CLEAR (Coordinated Lysosomal Expression and
Regulation) network of autophagy and lysosomal genes
(Supplementary Fig. 5A). A recent study demonstrated a
key role of TFEB during ATRA-induced differentiation
[15]. We, therefore, investigated the relationship between
FASN and CLEAR network gene expression. Interestingly,
several TFEB downstream targets from the different cate-
gories (lysosomal hydrolases and accessory proteins,
lysosomal membrane, lysosomal acidification, non-
lysosomal proteins involved in lysosomal biogenesis and
autophagy) are negatively associated with FASN transcript
levels in two primary AML patient cohorts from TCGA
analyzed using the UCSC Xena platform [60] and the Blood
spot gene expression profiles data base [41] (Fig. 6A,
Supplementary Fig. 5B-C Supplementary Table 1–2). Fur-
thermore, analyzing RNA-seq data of NB4 cells treated
with ATRA confirmed a reduction of FASN expression
Fig. 3 Reducing FASN protein levels improves ATRA-mediated
neutrophil differentiation of APL cells. A–D NB4 cells were stably
transduced with non-targeting shRNA (SHC002) or shRNAs targeting
FASN (shFASN_1 and shFASN_2) lentiviral vectors and differentiated
with 1 μM ATRA for 1, 2 or 3 days. A FASN western blot analysis of
control and shFASN (shFASN_1, _2) expressing NB4 cell populations.
B–C NBT reduction in ATRA-treated NB4 control (SHC002) and
FASN knockdown (shFASN_1, _2) cells. B Representative images of
NBT assays in control and FASN depleted NB4 cells. Scale 20 µM. C
Quantification of the percentage of NBT+ cells. D Flow cytometry
analysis of CD11b surface expression NB4 control (SHC002) and
FASN knockdown (shFASN_1, _2) NB4 cells upon ATRA treatment.
E–G NB4 cells were treated with the indicated C75 concentrations for
3 days in combination with ATRA. E–F NBT reduction during
ATRA-mediated neutrophil differentiation of NB4 control and C75
treated cells. E Representative images of NBT assays in control and
C75 treated NB4 cells upon ATRA-mediated differentiation. Scale 20
µM. F Quantification of the percentage of NBT+ cells. G Flow
cytometry analysis of CD11b surface expression in NB4 control and
C75 treated cells upon ATRA-mediated differentiation. H–J NB4 cells
were treated with the indicated Orlistat concentrations for 3 days in
combination with ATRA. H–I NBT reduction during ATRA-mediated
neutrophil differentiation of NB4 control and Orlistat treated cells.
H Representative images of NBT assays in control and Orlistat treated
NB4 cells upon ATRA-mediated differentiation. Scale 20 µM
I Quantification of the percentage of NBT+ cells. J Flow cytometry
analysis of CD11b surface expression in NB4 control and Orlistat
treated cells upon ATRA-mediated differentiation. Data are repre-
sented as a mean (n= 3), Error bars: SD.
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paralleled by increased TFEB and TFEB target gene tran-
script levels [15] (Fig. 6B). To test if the FASN-mTOR
pathway is involved in regulating TFEB activity, we ana-
lyzed the cellular localization of TFEB upon ATRA treat-
ment in NB4 control and FASN depleted cells. First, we
investigated if TFEB translocates to the nucleus following
ATRA treatment and if this translocation is paralleled by an
increase in lysosome numbers (LAMP1+ dots), assessed by
immunofluorescence microscopy (Supplementary Fig. 6A-
B). Indeed, ATRA treatment resulted in increased LAMP1+
Fig. 4 FASN expression is linked to increased mTOR activity. A–C
Autophagy induction in NB4 shFASN cells treated with 1 µM ATRA
for 24 h, in the presence or absence of BafA1 during the last 2 h before
harvesting. A–B NB4 control (SHC002) and FASN knockdown
(shFASN_1, _2) cells were subjected to LC3B immunofluorescence.
A Representative picture of LC3B punctae in NB4 control (SHC002)
and FASN knockdown (shFASN_1, _2) cells. Scale: 10 µm.
B Quantification of autophagy flux. Three independent experiments
were quantified as described in [13]. C Scheme of mTOR activity on
the ULK1 complex. D NB4 control (SHC002) and FASN knockdown
(shFASN_1, _2) cells were treated for 1–3 days with ATRA. Total
protein was extracted and subjected to immunoblotting using anti-
FASN, anti-pmTOR(Ser2448), anti- pULK1(Ser757), anti-ULK1,
anti-pATG13(Ser318) and anti-ATG13 antibodies. E–F Relative
protein expressions of two independent experiments were normalized
to total protein or the respective non-phosphorylated protein and
quantified using ImageJ software (NIH, Bethesda, MD, USA).
E pmTOR(Ser2448) normalized to total protein. F pULK1(Ser758)
normalized to total ULK1. G pATG13(Ser318) normalized to total
ATG13. Results shown are from at least two biological duplicates.
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dot formation and nuclear translocation of TFEB. Interest-
ingly, TFEB nuclear translocation occurs faster in FASN
depleted NB4 cells compared to control cells (Fig. 6C),
consistent with an increase in LAMP1+ dot formation
(Fig. 6D-E). Furthermore, we treated cells with Acridine
Orange to quantify the lysosomal integrity by flow cyto-
metry. Acridine Orange is a cell-permeable fluorescent dye
that, when excited at 488 nm, emits light at 530 nm
(GREEN) in its monomeric form but shifts its emission to
680 nm (RED) when accumulating and precipitating inside
lysosomes. Therefore, we measured the RED/GREEN ratio
of Acridine Orange stained cells by flow cytometry as
previously described [61]. We found that ATRA treatment
shifted the ratio towards the red channel (Supplementary
Fig. 6C). Reducing FASN expression further accelerated the
increase of the RED/GREEN ratio indicating enhanced
lysosome biogenesis (Fig. 6G-H). These results suggest that
FASN expression impairs TFEB translocation to the
nucleus and therefore reduces lysosome biogenesis
We then evaluated the effect of FASN expression on the
transcription of the following TFEB target genes: BECN1,
GABARAP, STK4 and WDR45. All four TFEB targets
showed increased expression upon ATRA treatment, in line
with previous studies [14, 15, 62] (Fig. 6I). Knock down of
FASN led to a further increase in the expression of 3/4
TFEB targets analyzed (Fig. 6I). These results suggest that
FASN retardation of TFEB translocation to the nucleus
attenuates CLEAR network gene transcription.
Then, we tested whether we can obtain similar results by
lowering FASN protein levels using EGCG. Using different
Fig. 5 FASN localizes at the lysosome to increase mTOR activity.
A NB4 cells were treated as in 2D and fixed and stained for endo-
genous FASN (red) and LAMP1 (green) protein. The colocalization
analysis was performed using ImageJ software. Scale: 10 µm. Results
shown are from at least two biological duplicates. B–D NB4 control
(SHC002) and FASN knockdown (shFASN_1, _2) cells were treated
for 1–3 days with ATRA. B Immunofluorescence microscopy of
endogenous mTOR (green) and LAMP1 (red). The colocalization
analysis was performed using ImageJ software. Scale: 10 µm. C Total
protein was extracted and subjected to immunoblotting using anti-
FASN, anti-pmTOR(Ser2448), anti-pTFEB(Ser211), anti-TFEB, anti-
pAKT(Ser473) anti-PTEN and anti-p4E-BP1 (Thr37/46) antibodies.
D Relative protein expressions of two independent experiments were
normalized to total protein or the respective non-phosphorylated pro-
tein and quantified using ImageJ software (NIH, Bethesda, MD, USA).
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Fig. 6 FASN expression negatively associates with TFEB activity.
A Heatmaps of the correlation between FASN and TFEB target genes
extracted from the TCGA-AML cohort analyzed by the UCSD xena
platform and from the blood spot data bank (Spearman, p values in
Supplementary Table 1 and 2). B mRNA sequencing data of NB4 cells
treated with ATRA. Relative expression of FASN, TFEB and TFEB
transcriptional targets involved in lysosomal function and biogenesis
are shown. C–H NB4 control (SHC002) and FASN knockdown
(shFASN_1, _2) cells were treated for 1–3 days with ATRA. C
Immunofluorescence microscopy of endogenous TFEB (red) and α-
tubulin (green). IgG staining was used as negative control. Nuclei were
stained with DAPI (blue). D Immunofluorescence microscopy of
endogenous LAMP1 (red). Nuclei were stained with DAPI (blue).
Scale: 10 µm (E) LAMP1 punctae quantification of cells shown in (D).
Scale: 10 µm (F–H) Acridine Orange staining. F Histogram repre-
sentation of the ratio between RED and GREEN of NB4 control
(SHC002) cells treated as described in 6 C. G Representative histo-
gram of NB4 control (SHC002) and FASN knockdown (shFASN_1,
_2) cells treated as in 6 C. H Overton percentage positive quantifica-
tion of the RED/GREEN ratio of NB4 control (SHC002) and FASN
knockdown (shFASN_1, _2) cells treated with ATRA at indicated
times. I Evaluation of BECN1, GABARAP, STK4 and WDR45 mRNA
transcripts was done by qPCR. Values were normalized to the HMBS
housekeeping gene. Results shown are from at least two biological
duplicates.
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EGCG concentrations, we found a decrease in mTOR
phosphorylation at Ser2448 (Supplementary Fig. 7A), an
increase of TFEB translocation to the nucleus (Supple-
mentary Fig. 7B), an increase of LAMP1+ vesicles (Sup-
plementary Fig. 8A-B) and an increase of the RED/GREEN
ratio in Acridine Orange stained cells similar to the results
seen in FASN-depleted APL cells (Supplementary Fig. 8C-
E). In addition, we found an upregulation of 3/4 TFEB
target genes in presence of EGCG in line with our FASN
knockdown experiments (Supplementary Fig. 7C).
Together, these data suggest that high FASN expression
results in lower autophagic activity and decreased lysoso-
mal capacity due to increased mTOR activity causing TFEB
inhibition.
Lowering FASN expression improves ATRA therapy
in non-APL AML cell lines by inhibiting the mTOR
pathway
Given the fact that APL cells treated with EGCG demon-
strated improved response to ATRA therapy, we asked if
EGCG can be beneficial to other AML subtypes that are
refractory to ATRA treatment. We and others previously
demonstrated a positive impact of co-treating HL60 AML
cells, a non-APL AML cell line that responds to ATRA,
with EGCG and ATRA [48, 63, 64]. Therefore, we tested if
ATRA-refractory AML cell lines with different genetic
backgrounds, namely MOLM-13 (FLT3-ITD+) and OCI/
AML2 (DNMT3A R635W mutation), would respond to
ATRA in combination with EGCG. MOLM-13 showed
significantly increased granulocytic differentiation upon the
combination treatment as shown by CD11b surface
expression while OCI/AML2 cells showed a clear but non-
significant trend toward improved granulocytic differentia-
tion (Fig. 7A-B). In addition, MOLM-13 and OCI/AML2-
showed an increase in the RED/GREEN ratio when stained
with Acridine Orange (Fig. 7C-D). Furthermore, co-
treatment with ATRA and EGCG led to a decrease in
mTOR activity as seen by a decrease in mTOR (Ser2448)
and ULK1 (Ser758) phosphorylation. In MOLM-13 cells,
this was paralleled by an increase of ATG13 (Ser318)
phosphorylation (Fig. 7E-F). We further confirmed these
data by genetically inhibiting FASN in MOLM-13 (Fig. 8A)
and OCI/AML2 (Fig. 8B) cells. Depleting FASN in both
cell lines caused an increase of CD11b surface expression
after 3 days of ATRA treatment (Fig. 8C-D), coupled with
Fig. 7 Lowering FASN protein expression levels improves ATRA
therapy in non-APL AML cells. A–F MOLM-13 (A, C, E), and
OCI-AML2 (B, D, F) cells were treated with ATRA and different
concentrations of EGCG (5 µM, 10 µM and 15 µM) for 3 days (n= 3).
A–B CD11b surface staining was analyzed by flow cytometry. Box
blot represent the median fluorescence intensity (MFI) of CD11b
positive cells. C–D Acridine Orange staining. Analysis was performed
as in Fig. 6E-G. E–F Total protein extracted from MOLM-13 and
OCI-AML2 cells treated as in 7 A/B were subjected to immunoblotting
using anti-FASN, anti-pmTOR(Ser2448), anti- pULK1(Ser757), anti-
ULK1, anti-pATG13(Ser318) and anti-ATG13 antibodies. Results
shown are from at least two biological duplicates.
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an increased RED/GREEN ratio when stained for Acridine
Orange (Fig. 8E-F) and lower mTOR activity (Fig. 8G-H).
Interestingly, we found more variation in lysosomal com-
partment changes between the experimental duplicates upon
ATRA when cells were treated with EGCG (Fig. 7D, F)
than in the knockdown cells (Fig. 8F, H), perhaps reflecting
the lower specificity of EGCG.
Together, our data suggest that reducing FASN expres-
sion can increase lysosomal biogenesis and improve the
differentiation of non-APL AML cells. We, therefore, pro-
pose that FASN is recruited to lysosomes in AML cells
resulting in activation of mTOR and sequestration of TFEB
in the cytoplasm (Fig. 8I). FASN degradation via autophagy
resulted in activation of TFEB and its downstream targets
(Fig. 8I).
Discussion
In this study, we aimed at further dissecting the function of
FASN in AML cells and, in particular, its potential role in
the differentiation of immature AML blasts. We showed
Fig. 8 MOLM-13 and OCI/AML2 were stably transduced with 2
independent shRNA targeting FASN (n= 3). A–B FASN knock-
down efficiency was validated in MOLM-13 (A) and OCI/AML2
(B) by western blotting. C–H MOLM-13 and OCI/AML2 control
and FASN knockdown cells were treated with ATRA for 3 days.
C–D CD11b surface marker expression was analyzed as in
(A–B). E–F Acridine Orange staining analysis was performed as in
7E-G. G–H Western blot analysis of total protein was extracted and
subjected to immunoblotting using anti-FASN, anti-pmTOR(Ser2448),
anti- pULK1(Ser757), anti-ULK1, anti-pATG13(Ser318) and anti-
ATG13 antibodies. Results shown are from at least two biological
duplicates. I FASN localizes to lysosomes in AML with mTOR
leading to the phosphorylation of TFEB and its sequestration in the
cytoplasm. ATRA treatment resulted in FASN degradation by autop-
hagy and thus TFEB translocation to the nucleus and activation of
lysosomal biogenesis.
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that knocking down FASN accelerated ATRA-induced dif-
ferentiation, while inhibition of its enzymatic function by
pharmacological inhibitors such as C75 or Orlistat had no
effect. Furthermore, we found that FASN expression acti-
vates mTOR resulting in sequestration of TFEB to the
cytoplasm. Importantly, inhibiting FASN expression, in
combination with ATRA treatment, improved differentia-
tion therapy in non-APL AML cells.
Several studies demonstrated a tumor suppressor role
of autophagy in AML cells. Autophagy can support
degradation of leukemic oncogenes in AML such as
FLT3-ITD and PML-RARA [10, 65, 66]. Furthermore,
activation of mTORC1 is crucial for leukemia cell pro-
liferation at least partially due to its inhibitory effect on
autophagy [42, 67]. Accordingly, inhibition of autophagy
leads to acceleration of MLL-ENL AML leukemia pro-
gression in vivo [42]. Our results indicate that increased
FASN expression might be a key activator of mTORC1 in
AML. Surprisingly, we found that reducing FASN protein
levels, but not inhibition of catalytic function, promotes
ATRA-induced differentiation. Recently, Bueno et al.
demonstrated that FASN is key during the transformation
from 2- to 3-dimensional growth of cancer cells. This
transformation step does not depend on the FASN bio-
synthetic products palmitate, further hinting to at impor-
tant non-catalytic functions of FASN in carcinogenesis
[68]. Further studies on the interplay between FASN,
mTOR and autophagy in AML transformation, progres-
sion and therapy resistance are warranted to improve our
understanding of cell fate decisions and could potentially
open new avenues to tackle this disease with improved
differentiation therapies.
We further confirmed that EGCG positively impacts
cellular differentiation in additional AML subtypes in vitro
[48, 63, 64]. Searching for potential mediators of the
positive effects of EGCG observed during ATRA-induced
differentiation, we previously found that EGCG induces
expression of the Ca2+/calmodulin-regulated serine/threo-
nine kinase DAPK2. DAPK2 plays a major role in granu-
locytic differentiation and decreased DAPK2 expression in
APL cells can be restored by ATRA and EGCG treatment
[13, 38, 48]. DAPK2 also negatively regulates mTOR via
phosphorylation of raptor at Ser721 as shown in HeLa cells
[69]. Therefore, a potential impact of FASN on DAPK2
activity in a leukemic context warrants further investigation.
Interestingly, treating APL cells with ATRA had a
negative effect on FASN protein levels (Fig. 1C), and we
demonstrated that ATRA-induced autophagy contributes to
FASN protein degradation. Furthermore, FASN reduction
led to increased lysosomal biogenesis suggesting a negative
feedback loop between autophagy and FASN. It is reason-
able to hypothesize that the more AML cells differentiate
the more they become competent to degrade long-lived
proteins including FASN. In addition, inhibiting mTOR
using Rapamycin or Everolimus accelerates differentiation
of APL cells [10, 12]. While PI3K/AKT/mTOR pathways
are activated in about 80% of AML cases, mTOR inhibitors
had only modest effects in AML therapy [70, 71]. Fur-
thermore, despite its role in leukemia cells, mTOR activity
is crucial for hematopoietic stem cell (HSC) proliferation
and self-renewal potential [72]. Therefore, targeting FASN
with low expression in healthy progenitor cells would allow
activation of autophagy in AML cells sparing healthy HSC
cells in the bone marrow. In our hands, EGCG treatment
only demonstrated partial effects regarding improved dif-
ferentiation when compared to knocking down FASN in
non-APL AML cells. Therefore, a more specific FASN
expression inhibitor is needed to improve differentiation
therapy in non-APL AML patients.
Indeed, it would be of interest to study the transcriptional
regulation of FASN to influence its expression in
autophagy-deficient cells. Consistently, there are several
studies showing that FASN transcription is positively
affected by retinoic acids [73, 74]. However, transcription
induction is not mediated by a classic retinoic acid-
responsive element but rather by the indirect influence of
retinoic acid via cis-regulatory elements. Since this involves
different cofactors it is tempting to speculate that tran-
scriptional activation might switch to repression depending
on the cellular context including specific retinoid-binding
proteins and cofactors. We previously found that members
of the KLF transcription factor family are often deregulated
in primary AML patient samples. Among the different KLF
family members downregulated in AML, particularly KLF5
turned out to be essential for granulocytic differentiation
[75, 76]. KLF5 forms a transcriptionally active complex
with RAR/RXR heterodimers [77, 78]. Interestingly, ecto-
pic expression of KLF5 in U937 non-APL AML cell line
was sufficient to significantly increase ATRA-induced dif-
ferentiation [79]. We hypothesize that KLF5 negatively
regulates FASN transcription in AML cells via the RAR/
RXR complex.
In summary, our data suggest that inducing FASN pro-
tein degradation is likely to be beneficial for differentiation
therapy of non-APL AML cells as this will impede mTOR
and promote TFEB transcriptional activity and autophagy.
Furthermore, high FASN expression in AML is partially
based on attenuated autophagy activity in this disease.
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